References
- Vieira AC, Hofling-Lima AL, Mannis MJ. Ocular rosacea–a review. Arq Brasil Oftalmol. 2012;75:363–369. doi:https://doi.org/10.1590/S0004-27492012000500016.
- Vieira AC, Mannis MJ. Ocular rosacea: common and commonly missed. J Am Acad Dermatol. 2013;69:S36–41. doi:https://doi.org/10.1016/j.jaad.2013.04.042.
- Lazaridou E, Fotiadou C, Ziakas NG, Giannopolou C, Apalla Z, Ionnides D. Clinical and laboratory study of ocular rosacea in northern Greece. J Eur Acad Dermatol Venereol. 2011;25:1428–1431. doi:https://doi.org/10.1111/j.1468-3083.2011.03995.x.
- Ghanem VC, Mehra N, Wong S, Mannis MJ. The prevalence of ocular signs in acne rosacea: comparing patients from ophthalmology and dermatology clinics. Cornea. 2003;22:230–233. doi:https://doi.org/10.1097/00003226-200304000-00009.
- Akpek EK, Merchant A, Pinar V, Foster CS. Ocular rosacea: patient characteristics and follow-up. Ophthalmology. 1997;104:1863–1867. doi:https://doi.org/10.1016/S0161-6420(97)30015-3.
- Ramamurthi S, Rahman MQ, Dutton GN, Ramaesh K. Pathogenesis, clinical features and management of recurrent corneal erosions. Eye (Lond). 2006;20:635–644. doi:https://doi.org/10.1038/sj.eye.6702005.
- Al Arfaj K, Al Zamil W. Spontaneous corneal perforation in ocular rosacea. Middle East Afr J Ophthalmol. 2010;17:186–188. doi:https://doi.org/10.4103/0974-9233.63070.
- Wladis EJ, Adam AP. Treatment of ocular rosacea. Surv Ophthalmol. 2018;63:340–346. doi:https://doi.org/10.1016/j.survophthal.2017.07.005.
- Wladis EJ, Carlson JA, Wang MS, Bhoiwala DP, Adam AP. Toll-like receptors and vascular markers in ocular rosacea. Ophthal Plast Reconst Surg. 2013;29:290–293. doi:https://doi.org/10.1097/IOP.0b013e318293764c.
- Yamasaki K, Kanada K, Macleod DT, Borkowski AW, Morizane S, Nakatsuji T, et al. TLR2 expression is increased in rosacea and stimulates enhanced serine protease production by keratinocytes. J Invest Dermatol. 2011;131:688–697. doi:https://doi.org/10.1038/jid.2010.351.
- Newton K, Dixit VM. Signaling in innate immunity and inflammation. Cold Spring Harb Perspect Biol. 2012;4:a006049–a006049. doi:https://doi.org/10.1101/cshperspect.a006049.
- Wladis EJ, Swamy S, Herrmann A, Yang J, Carlson JA, Adam AP. Activation of p38 and Erk mitogen-associated protein kinases signaling in ocular rosacea. Invest Ophthalmol Vis Sci. 2017;58:843–848. doi:https://doi.org/10.1167/iovs.16-20275.
- Wladis EJ, Lau KW, Adam AP. Nuclear factor kappa-B is enriched in eyelid specimens of rosacea: implications for pathogenesis and therapy. Am J Ophthalmol. 2019;201:72–81. doi:https://doi.org/10.1016/j.ajo.2019.01.018.
- Wladis EJ, Iglesias BV, Adam AP, Gosselin EJ. Molecular biologic assessment of ocular rosacea. Ophthal Plast Reconstr Surg. 2012;28:246–250. doi:https://doi.org/10.1097/IOP.0b013e31824dd9d4.
- Deguine J, Barton GM. MyD88: a central player in innate immune signaling. F1000 Prime Rep. 2014;6:97. doi:https://doi.org/10.12703/P6-97.
- Seo S-W, Park S-K, Oh S-J, Shin OS. TLR4-mediated activation of the ERK pathway following UVA irradiation contributes to increased cytokine and MMP expression in senescent dermal fibroblasts. PLoS One. 2018;13:e0202323. doi:https://doi.org/10.1371/journal.pone.0202323.
- Lee Y, Kim H, Kim S, Shin MH, Kim YK, Kim KH, et al. Myeloid differentiation factor 88 regulates basal and UV-induced expressions of IL-6 and MMP-1 in human epidermal keratinocytes. J Invest Dermatol. 2009;129:460–467. doi:https://doi.org/10.1038/jid.2008.261.
- Sharma BR, Karki R, Lee E, Zhu Q, Gurung P, Kanneganti T-D. Innate immune adaptor MYD88 deficiency prevents skin inflammation in SHARPIN-deficient mice. Cell Death Differ. 2019;26:741–750. doi:https://doi.org/10.1038/s41418-018-0159-7.
- Reins RY, Lema C, Courson J, Cunnen CME, Redfern RL. MyD88 deficiency protects against dry eye-induced damage. Invest Ophthalmol Vis Sci. 2018;59:2967–2976. doi:https://doi.org/10.1167/iovs.17-23397.
- Sonawane S, Khanolkar V, Namawari A, Chaudhary S, Gandhi S, Tibrewal S, et al. Ocular surface extracellular DNA and nuclease activity imbalance: a new paradigm for inflammation in dry eye disease. Invest Ophthalmol Vis Sci. 2012;53:8253–8263. doi:https://doi.org/10.1167/iovs.12-10430.
- Yang F-M, Fan D, Yang X-Q, Zhu F-H, Shao M-J, Li Q, et al. The artemisinin analog SM934 alleviates dry eye disease in rodent models by regulating TLR4/NF-κB/NLRP3 signaling. Acta Pharmacol Sin. 2020; epub ahead of print. doi:https://doi.org/10.1038/s41401-020-0484-5.
- Liu J-H, He L, Zou Z-M, Ding Z-C, Zhang X, Wang H, et al. A novel inhibitor of homodimerization targeting MyD88 ameliorates renal interstitial fibrosis by counteracting TGF-β1-induced EMT in Vivo and in Vitro. Kidney Blood Press Res. 2018;43:1677–1687. doi:https://doi.org/10.1159/000494745.
- Su Q, Li L, Sun Y, Li H, Weidong MI, Jiang Y. Effects of the TLR4/MyD88/NF-KB signaling pathway on NLRP3 inflammasome in coronary microembolization-induced myocardial injury. Cell Physiol Biochem. 2018;47:1497–1508. doi:https://doi.org/10.1159/000490866.
- Jin X, Shi Q, Li Q, Zhou L, Wang J, Jiang L, et al. CRL3-SOP ubiquitin ligase complex suppresses the growth of diffuse large B-cell lymphoma by negatively regulating the MyD88/NFKB signaling. Leukemia. 2020;34:1305–1314. doi:https://doi.org/10.1038/s41375-019-0661-z.
- Lionakis MS, Dunleavy K, Roschewski M, Wideman BC, Butman JA, Schmitz R, et al. Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma. Cancer Cell. 2017;31:833–845. doi:https://doi.org/10.1016/j.ccell.2017.04.012.
- Treon SP, Tripsas CK, Meid K, Heffner LT, Eradat H, Badros AZ, et al. Ibrutinib in previously treated Waldenström’s macroglobulinemia. N Eng J Med. 2017;372:1430–1440. doi:https://doi.org/10.1056/NEJMoa1501548.